Stocks · News reference
HC Wainwright & Co. analyst Brandon Folkes reiterates Traws Pharma (NASDAQ:TRAW) with a Neutral and maintains $1 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.34) by 51.52 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the
Read original at benzingaFiled: 2026-08-14 AccNo: 0001104659-26-097226 Size: 312 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgar